Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg—IL PSO (Italian Landscape Psoriasis)
Abstract Introduction Tildrakizumab is a monoclonal antibody targeting interleukin (IL)-23 approved for the treatment of moderate-to-severe plaque psoriasis across two different dosages (100 mg and 200 mg). The higher dosage is recommended for patients with a body weight ≥ 90 kg or a high disease bu...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-04-01
|
| Series: | Dermatology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s13555-025-01416-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850127918049525760 |
|---|---|
| author | Mario Valenti Luciano Ibba Sara Di Giulio Luigi Gargiulo Piergiorgio Malagoli Anna Balato Federico Bardazzi Francesco Loconsole Martina Burlando Anna E. Cagni Norma Cameli Carlo G. Carrera Andrea Carugno Aldo Cuccia Paolo Dapavo Eugenia V. Di Brizzi Valentina Dini Maria C. Fargnoli Francesca M. Gaiani Claudio Guarneri Claudia Lasagni Gaetano Licata Angelo V. Marzano Matteo Megna Santo R. Mercuri Alessandra Michelucci Maria L. Musumeci Diego Orsini Romina Ortega Luca Potestio Luca Rapparini Simone Ribero Francesca Satolli Davide Strippoli Emanuele Trovato Marina Venturini Leonardo Zichichi Pina Brianti Antonio Costanzo Alessandra Narcisi |
| author_facet | Mario Valenti Luciano Ibba Sara Di Giulio Luigi Gargiulo Piergiorgio Malagoli Anna Balato Federico Bardazzi Francesco Loconsole Martina Burlando Anna E. Cagni Norma Cameli Carlo G. Carrera Andrea Carugno Aldo Cuccia Paolo Dapavo Eugenia V. Di Brizzi Valentina Dini Maria C. Fargnoli Francesca M. Gaiani Claudio Guarneri Claudia Lasagni Gaetano Licata Angelo V. Marzano Matteo Megna Santo R. Mercuri Alessandra Michelucci Maria L. Musumeci Diego Orsini Romina Ortega Luca Potestio Luca Rapparini Simone Ribero Francesca Satolli Davide Strippoli Emanuele Trovato Marina Venturini Leonardo Zichichi Pina Brianti Antonio Costanzo Alessandra Narcisi |
| author_sort | Mario Valenti |
| collection | DOAJ |
| description | Abstract Introduction Tildrakizumab is a monoclonal antibody targeting interleukin (IL)-23 approved for the treatment of moderate-to-severe plaque psoriasis across two different dosages (100 mg and 200 mg). The higher dosage is recommended for patients with a body weight ≥ 90 kg or a high disease burden (Psoriasis Area and Severity Index [PASI] ≥ 16 or the involvement of difficult-to-treat areas). We conducted a 52-week multicenter retrospective study to compare the effectiveness and safety of both dosages and assess their impact on specific patient subgroups. Methods We enrolled a total of 540 patients with high disease burden or body weight ≥ 90 kg; 177 and 363 were treated with tildrakizumab 200 mg and 100 mg, respectively. The effectiveness was evaluated in terms of PASI 90, PASI 100, and PASI ≤ 2 at weeks 16, 28, and 52. We also performed subanalyses according to the body weight (≥ 90 kg), PASI ≥ 16, prior biologic exposure, involvement of difficult-to-treat areas, and the presence of at least one cardiometabolic comorbidity. Results After 16 weeks of treatment, a higher proportion of patients in the 200-mg group achieved PASI 90 and PASI 100 compared to those in the 100-mg group (43.5% vs. 34.3% and 36.4% vs. 24.2%, respectively). These results were sustained at 1 year, with PASI 90 and PASI 100 reached by 68.6% and 52.9% of patients in the 200-mg group, respectively, versus 57.3% and 35% in the 100-mg group. All subgroup analyses consistently indicated a trend toward greater effectiveness with tildrakizumab 200 mg, particularly in terms of PASI 90 and PASI 100 achievement at weeks 16 and 52. No differences in the safety profile were observed throughout the study period. Conclusion Our findings confirm the superior effectiveness of tildrakizumab 200 mg over 100 mg in specific subgroups of patients with a comparable safety profile across the study period. |
| format | Article |
| id | doaj-art-d84d35955a844a7cabc904dc0d0fd7b2 |
| institution | OA Journals |
| issn | 2193-8210 2190-9172 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Dermatology and Therapy |
| spelling | doaj-art-d84d35955a844a7cabc904dc0d0fd7b22025-08-20T02:33:31ZengAdis, Springer HealthcareDermatology and Therapy2193-82102190-91722025-04-011561427144010.1007/s13555-025-01416-zOptimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg—IL PSO (Italian Landscape Psoriasis)Mario Valenti0Luciano Ibba1Sara Di Giulio2Luigi Gargiulo3Piergiorgio Malagoli4Anna Balato5Federico Bardazzi6Francesco Loconsole7Martina Burlando8Anna E. Cagni9Norma Cameli10Carlo G. Carrera11Andrea Carugno12Aldo Cuccia13Paolo Dapavo14Eugenia V. Di Brizzi15Valentina Dini16Maria C. Fargnoli17Francesca M. Gaiani18Claudio Guarneri19Claudia Lasagni20Gaetano Licata21Angelo V. Marzano22Matteo Megna23Santo R. Mercuri24Alessandra Michelucci25Maria L. Musumeci26Diego Orsini27Romina Ortega28Luca Potestio29Luca Rapparini30Simone Ribero31Francesca Satolli32Davide Strippoli33Emanuele Trovato34Marina Venturini35Leonardo Zichichi36Pina Brianti37Antonio Costanzo38Alessandra Narcisi39Dermatology Unit, IRCCS Humanitas Research HospitalDermatology Unit, IRCCS Humanitas Research HospitalDermatology Unit, IRCCS Humanitas Research HospitalDermatology Unit, IRCCS Humanitas Research HospitalDepartment of Dermatology, Dermatology Unit Azienda Ospedaliera San Donato MilaneseDermatology Unit, University of Campania L. VanvitelliDermatology Unit, IRCCS Azienda Ospedaliero-Universitaria Di BolognaDepartment of Dermatology, University of BariDepartment of Dermatology, Dipartimento di Scienze Della Salute (DISSal), University of Genoa, IRCCS Ospedale Policlinico San MartinoUnità Operativa Dipartimentale di Dermatologia e Venereologia IRCCS San GerardoUOC Clinical Dermatology, Dermatological Institute S. Gallicano, IRCCSDermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore PoliclinicoDermatology Unit, Department of Medicine and Surgery, University of InsubriaUnit of Dermatology, San Donato HospitalDepartment of Biomedical Science and Human Oncology, Second Dermatologic Clinic, University of TurinDermatology Unit, University of Campania L. VanvitelliDepartment of Dermatology, University of PisaUOC Clinical Dermatology, Dermatological Institute S. Gallicano, IRCCSDepartment of Dermatology, Dermatology Unit Azienda Ospedaliera San Donato MilaneseDepartment of Biomedical and Dental Sciences and Morphofunctional Imaging, University of MessinaDermatological Clinic, Department of Specialized Medicine, University of ModenaU.O.C. Dermatology Unit, “S. Antonio Abate” HospitalDermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore PoliclinicoSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico IIDermatology and Cosmetology Unit, IRCCS San Raffaele HospitalDepartment of Dermatology, University of PisaDermatology Clinic, University of CataniaUOC Clinical Dermatology, Dermatological Institute S. Gallicano, IRCCSDermatology Clinic, University of CataniaSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico IIDermatology Unit, IRCCS Azienda Ospedaliero-Universitaria Di BolognaDepartment of Biomedical Science and Human Oncology, Second Dermatologic Clinic, University of TurinUnit of Dermatology, University of ParmaDermatology Unit, ASST Lecco, Alessandro Manzoni HospitalUnit of Dermatology, Department of Medical, Surgical and Neurological Sciences, University of SienaDermatology Department, University of Brescia, ASST Spedali Civili of BresciaU.O.C. Dermatology Unit, “S. Antonio Abate” HospitalDermatology and Cosmetology Unit, IRCCS San Raffaele HospitalDermatology Unit, IRCCS Humanitas Research HospitalDermatology Unit, IRCCS Humanitas Research HospitalAbstract Introduction Tildrakizumab is a monoclonal antibody targeting interleukin (IL)-23 approved for the treatment of moderate-to-severe plaque psoriasis across two different dosages (100 mg and 200 mg). The higher dosage is recommended for patients with a body weight ≥ 90 kg or a high disease burden (Psoriasis Area and Severity Index [PASI] ≥ 16 or the involvement of difficult-to-treat areas). We conducted a 52-week multicenter retrospective study to compare the effectiveness and safety of both dosages and assess their impact on specific patient subgroups. Methods We enrolled a total of 540 patients with high disease burden or body weight ≥ 90 kg; 177 and 363 were treated with tildrakizumab 200 mg and 100 mg, respectively. The effectiveness was evaluated in terms of PASI 90, PASI 100, and PASI ≤ 2 at weeks 16, 28, and 52. We also performed subanalyses according to the body weight (≥ 90 kg), PASI ≥ 16, prior biologic exposure, involvement of difficult-to-treat areas, and the presence of at least one cardiometabolic comorbidity. Results After 16 weeks of treatment, a higher proportion of patients in the 200-mg group achieved PASI 90 and PASI 100 compared to those in the 100-mg group (43.5% vs. 34.3% and 36.4% vs. 24.2%, respectively). These results were sustained at 1 year, with PASI 90 and PASI 100 reached by 68.6% and 52.9% of patients in the 200-mg group, respectively, versus 57.3% and 35% in the 100-mg group. All subgroup analyses consistently indicated a trend toward greater effectiveness with tildrakizumab 200 mg, particularly in terms of PASI 90 and PASI 100 achievement at weeks 16 and 52. No differences in the safety profile were observed throughout the study period. Conclusion Our findings confirm the superior effectiveness of tildrakizumab 200 mg over 100 mg in specific subgroups of patients with a comparable safety profile across the study period.https://doi.org/10.1007/s13555-025-01416-zAnti-IL-23BiologicsPsoriasisReal-LifeTildrakizumab |
| spellingShingle | Mario Valenti Luciano Ibba Sara Di Giulio Luigi Gargiulo Piergiorgio Malagoli Anna Balato Federico Bardazzi Francesco Loconsole Martina Burlando Anna E. Cagni Norma Cameli Carlo G. Carrera Andrea Carugno Aldo Cuccia Paolo Dapavo Eugenia V. Di Brizzi Valentina Dini Maria C. Fargnoli Francesca M. Gaiani Claudio Guarneri Claudia Lasagni Gaetano Licata Angelo V. Marzano Matteo Megna Santo R. Mercuri Alessandra Michelucci Maria L. Musumeci Diego Orsini Romina Ortega Luca Potestio Luca Rapparini Simone Ribero Francesca Satolli Davide Strippoli Emanuele Trovato Marina Venturini Leonardo Zichichi Pina Brianti Antonio Costanzo Alessandra Narcisi Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg—IL PSO (Italian Landscape Psoriasis) Dermatology and Therapy Anti-IL-23 Biologics Psoriasis Real-Life Tildrakizumab |
| title | Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg—IL PSO (Italian Landscape Psoriasis) |
| title_full | Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg—IL PSO (Italian Landscape Psoriasis) |
| title_fullStr | Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg—IL PSO (Italian Landscape Psoriasis) |
| title_full_unstemmed | Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg—IL PSO (Italian Landscape Psoriasis) |
| title_short | Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg—IL PSO (Italian Landscape Psoriasis) |
| title_sort | optimizing tildrakizumab dosing in psoriasis a 52 week multicenter retrospective study comparing 100 mg and 200 mg il pso italian landscape psoriasis |
| topic | Anti-IL-23 Biologics Psoriasis Real-Life Tildrakizumab |
| url | https://doi.org/10.1007/s13555-025-01416-z |
| work_keys_str_mv | AT mariovalenti optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis AT lucianoibba optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis AT saradigiulio optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis AT luigigargiulo optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis AT piergiorgiomalagoli optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis AT annabalato optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis AT federicobardazzi optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis AT francescoloconsole optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis AT martinaburlando optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis AT annaecagni optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis AT normacameli optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis AT carlogcarrera optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis AT andreacarugno optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis AT aldocuccia optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis AT paolodapavo optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis AT eugeniavdibrizzi optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis AT valentinadini optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis AT mariacfargnoli optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis AT francescamgaiani optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis AT claudioguarneri optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis AT claudialasagni optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis AT gaetanolicata optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis AT angelovmarzano optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis AT matteomegna optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis AT santormercuri optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis AT alessandramichelucci optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis AT marialmusumeci optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis AT diegoorsini optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis AT rominaortega optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis AT lucapotestio optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis AT lucarapparini optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis AT simoneribero optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis AT francescasatolli optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis AT davidestrippoli optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis AT emanueletrovato optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis AT marinaventurini optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis AT leonardozichichi optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis AT pinabrianti optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis AT antoniocostanzo optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis AT alessandranarcisi optimizingtildrakizumabdosinginpsoriasisa52weekmulticenterretrospectivestudycomparing100mgand200mgilpsoitalianlandscapepsoriasis |